NCCN Non-Small Cell Lung Cancer v.3.
2022 – Follow-up – March 9, 2022
Guideline Page
and Request
NSCL-3, NSCL-9, NSCL-10, NSCL-E
Internal request:
Panel review of the data in response to the FDA
approval of nivolumab in combination with platinum-
doublet chemotherapy for patients with resectable
(tumors ≥4 cm or node positive) NSCLC in the
neoadjuvant setting.
External request:
Submission from Bristol Myers Squibb, requesting the
addition of nivolumab in combination with platinum-
doublet chemotherapy as neoadjuvant systemic
treatment for adult patients with resectable (tumors ≥4
cm or node positive) NSCLC prior to definitive surgery.
Panel Discussion/References Institution Vote
YES NO ABSTAIN ABSENT
Based on the data in the noted references, the Panel 28 0 1 3
consensus supported the addition of nivolumab in
combination with platinum-doublet chemotherapy for
patients with resectable (tumors ≥4 cm or node positive)
NSCLC in the neoadjuvant setting. If an immune
checkpoint inhibitor is used in the pre-operative setting,
an immune checkpoint inhibitor should not be used in the
adjuvant setting.
This recommendation is a category 2A.
• Forde PM, Spicer J, Lu S, et al. Nivolumab (NIVO) +
platinum-doublet chemotherapy (chemo) vs chemo
as neoadjuvant treatment (tx) for resectable (IB-IIIA)
non-small cell lung cancer (NSCLC) in the phase 3
CheckMate 816 trial [abstract]. Cancer Res
2021;81:Abstract CT003.
• See Submission for references.